Get the Stockscreener App
126.35
0.15%
-0.19
Pre-market:
126.42
0.07
+0.06%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $126.35, with a volume of 8.16M.
It is down -0.15% in the last 24 hours and down -5.98% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$126.54
Open:
$126.15
24h Volume:
8.16M
Relative Volume:
1.23
Market Cap:
$219.83B
Revenue:
$43.11B
Net Income/Loss:
$13.98B
P/E Ratio:
15.83
EPS:
7.98
Net Cash Flow:
$6.66B
1W Performance:
+1.55%
1M Performance:
-5.98%
6M Performance:
-0.82%
1Y Performance:
+20.06%
1-Day Range:
$125.62
$126.99
1-Week Range:
$124.22
$126.99
52-Week Range:
$99.92
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.35 | 220.16B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.84 | 157.03B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
400.69 | 154.21B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.97 | 119.08B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.49 | 46.93B | 5.69B | 4.15B | 623.10M | 6.95 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Europe Defibrillator Market Forecast and Company Analysis Report 2025-2033 Featuring Medtronic, Philips, Nihon Kohden, Boston Scientific, Stryker, Asahi Kasei, LivaNova, and Abbott - GlobeNewswire Inc.
2nd Abbott Baby Formula Bellwether Falls Before Trial - Law360
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT) - MSN
Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating - Insider Monkey
RBC Capital Bullish on Abbott Laboratories, Raises Price Target to $147. - AInvest
Why is Abbott Laboratories stock attracting strong analyst attentionBuild wealth with steady, reliable stocks - jammulinksnews.com
Declining Stock and Solid Fundamentals: Is The Market Wrong About Abbott Laboratories (NYSE:ABT)? - Yahoo Finance
Continental Express wins fifth Abbott award - Sidney Daily News
Did Strong Q2 Results and Raised Guidance Just Shift Abbott Laboratories' (ABT) Investment Narrative? - simplywall.st
Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity - MSN
What analysts say about Abbott Laboratories stockConsistent high-performance stocks - PrintWeekIndia
Abbott Laboratories Stock Analysis and ForecastDynamic growth stocks - Autocar Professional
What drives Abbott Laboratories stock priceOutstanding capital appreciation - Autocar Professional
Abbott Laboratories (ABT): A Bull Case Theory - MSN
The Zacks Analyst Blog Highlights Wells Fargo, Abbott Laboratories, American Express, TSS and Maui Land & Pineapple - Yahoo Finance
Abbott Laboratories (ABT): I Am Very Upset With Abbott,” Says Jim Cramer - MSN
Top Stock Reports for Wells Fargo, Abbott & American Express - Yahoo Finance
Brianne Gardner's Top Picks: Abbott Labs, Chipotle Mexican Grill & Motorola Solutions - BNN Bloomberg
Jim Cramer Says He “Was Discouraged to Get a Mixed Update from Abbott Labs” - MSN
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Institutional owners may ignore Abbott Laboratories' (NYSE:ABT) recent US$10b market cap decline as longer-term profits stay in the green - Yahoo Finance
Notable healthcare headlines for the week: Trump’s tariff threats, J&J, Abbott Laboratories and Sarepta in focus - MSN
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Canada Oncology Market Outlook to 2033 - GlobeNewswire Inc.
Abbott Laboratories (NYSE:ABT) Q2 2025 Earnings Call Transcript - MSN
Low-Calorie Food Market Top Companies StudyAbbott - openPR.com
NEC Baby Formula Lawsuit & Settlement | July 2025 Update - Lawsuit Information Center
Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT) - 富途牛牛
Abbott Laboratories: Hold Rating Amid Mixed Performance and Sector Challenges - TipRanks
Abbott Labs stock rating reiterated at Buy by UBS despite guidance cut - Investing.com India
Abbott Laboratories falls after setting Q3 outlook below consensus - MSN
Abbott Laboratories Stock (ABT) Opinions on Q2 Earnings and Guidance Update - Quiver Quantitative
Is Abbott Laboratories (ABT) a Buy After the Earnings Selloff? - AInvest
Abbott Drops After Lowering Top End of Full-Year Guidance - MSN
Abbott Laboratories: A Medtech Titan Positioned for Growth in a Transformed Healthcare Landscape - AInvest
Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Abbott Laboratories Sheds Nearly 5% On A Rare Guidance Miss - MSN
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $135 to $159 - 富途牛牛
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):